Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt, Inc. reports developments as a life sciences and health-innovation platform with operating subsidiaries focused on diagnostics, precision oncology, and immune-system technologies. Company news includes updates on Ignite Proteomics, a commercial-stage precision oncology business that uses functional protein profiling to support cancer therapy selection, and Pearsanta, which is developing blood-based diagnostic tests including the Mitomic Endometriosis Test.
Recurring ADTX coverage also includes subsidiary leadership, clinical and research publications, acquisition activity, shareholder votes, reverse stock splits, Nasdaq listing matters, and other capital-structure actions tied to the company’s publicly traded common stock.
Aditxt Therapeutics, Inc. (ADTX) announced a partnership with Eazy Testing Inc. to offer AditxtScore™ for COVID-19 at Eazy Testing's locations in California. This immune monitoring service supplements Eazy Testing’s existing COVID-19 testing options, providing clients with valuable information about their immunity status. Both companies anticipate that this initiative will enhance demand for immunity testing as part of the ongoing pandemic response. Aditxt focuses on developing technologies to improve immune health.
Aditx Therapeutics (Nasdaq: ADTX) announced the appointment of Dr. Dolly B. Tyan as Senior Vice President of Clinical Development – Transplantation. Dr. Tyan will spearhead the company's organ rejection therapeutic program, advancing candidates toward clinical trials and developing new products. She brings over 45 years of experience in transplantation, having contributed to landmark technologies in the field. Her initial focus will be on Aditxt's Apoptotic DNA Immunotherapy™ (ADi™) for skin allografts. Aditxt aims for breakthroughs in organ acceptance and reducing transplant rejection.
Aditx Therapeutics (ADTX) announced a financing deal with an institutional investor, projected to net approximately $4.5 million. This funding aims to enhance the AditxtScore™ immune monitoring service and support general corporate needs. The investor will purchase a $6.0 million convertible promissory note, convertible at $4.00 per share, with repayments starting in July 2021. Additionally, Aditx raised $3.3 million from warrant exercises. CEO Amro Albanna emphasized that this funding will help meet the growing demand for immune monitoring services amid rising COVID-19 cases.
Aditx Therapeutics (ADTX) announced the launch of the AditxtScore™ Immune Monitoring Platform effective February 1, 2021. This platform includes AditxtScore™ for COVID-19, designed to assess an individual's infection and immunity status against SARS-CoV-2. The test will evaluate the virus's presence and measure antibody levels for neutralization. Aditxt plans to offer this as a Lab Developed Test (LDT) through CLIA-certified reference labs, enabling channel partners to efficiently integrate the service without extra resources.
Aditxt Therapeutics has announced a distribution agreement with Todos Medical for its AditxtScore™ for COVID-19. This service, which aims to monitor immunity against SARS-CoV-2, is expected to be available in January 2021. Todos Medical will manage blood sample collection and processing at Aditxt's CLIA-accredited center. AditxtScore™ will evaluate both antibody and neutralizing antibodies, with plans to expand into T-cell and B-cell assessments, making it a comprehensive immune profiling tool as vaccine rollouts increase. This agreement marks a significant commercial step for Aditxt.
Aditxt Therapeutics, a life sciences company focused on enhancing immune system health, will present at the 13th annual LD Micro Main Event on December 15, 2020, at 11:00 AM EST. CEO Amro Albanna will address a live audience in a virtual format, featuring a distinctive Q&A session with investors. The event, taking place on the Sequire Virtual Events platform, aims to deliver an engaging experience for both executives and investors. Aditxt is developing biotechnologies for immune monitoring and reprogramming, targeting issues like organ rejection and autoimmune diseases.
Aditxt Therapeutics, Inc. (ADTX), a company focused on immune system health, announced a review of data from its AditxtScore™ for COVID-19 by Dr. Drew Pinsky and CEO Amro Albanna. This event is part of an ongoing clinical study measuring immunity against COVID-19. The AditxtEngage™ event is set for December 1, 2020, and will stream live from the AditxtScore™ Center. Aditxt is developing technologies aimed at immune monitoring and reprogramming, addressing issues like organ rejection and autoimmune diseases. For more details, visit Aditxt's website.
Aditx Therapeutics, Inc. (Nasdaq: ADTX) has appointed Anthony Voorhies as Head of Business Development for AditxtScore™, enhancing its immune monitoring platform. Voorhies brings extensive experience in diagnostics and medical devices, having previously worked with Calroy Health Sciences and Itamar Medical. CEO Amro Albanna anticipates Voorhies' leadership will propel AditxtScore toward proactive immune diagnosis. Aditxt focuses on technologies to improve immune health, including personalized immune profiling and immune system reprogramming.
Aditx Therapeutics (Nasdaq: ADTX) has announced that its AditxtScore™ laboratory operations for immune monitoring have received CLIA certification, enabling the launch of AditxtScore™ for COVID-19 as a Laboratory Developed Test (LDT). The operations will be co-located with Salveo Diagnostics in Richmond, VA, facilitating a targeted commercial launch in January 2021. Aditxt is also pursuing Emergency Use Authorization (EUA) from the FDA for AditxtScore™, anticipated to lead to 510(k) clearance. CEO Amro Albanna emphasized the need for ongoing immune monitoring with new vaccines coming to market.
Aditx Therapeutics (Nasdaq: ADTX) provided a business update following its Form 10-Q filing. The company successfully completed its IPO and follow-on offering, now holding $13.7 million in cash as of September 30, 2020. Key developments include the introduction of the AditxtScore™ Monitoring platform for COVID-19 antibody detection, pending FDA Emergency Use Authorization. Aditxt aims to enhance immune health through innovative technologies, focusing on personalized immune monitoring and pre-clinical immune reprogramming.